In a small and selected set of cases, 46% of TP53-mutant endometrial cancers were reported to be homologous recombination deficient by functional RAD51 assessment.50 No data are yet available on the effect of PARP inhibition in patients with endometrial cancer, but combination treatment targeting homologous recombination deficiency using platinum-based chemotherapy with PARP inhibition or a combination of PARP and checkpoint inhibition seems attractive based on the similarities with high-grade ovarian cancer.61 The gene discussed is TP53; the disease is endometrial cancer.